Gabapentin
Product Images NDC 50090-4889

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-4889). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula for calculating creatinine clearance (CLCr), with adjustments for age, weight, serum creatinine, and a factor for female patients.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram of gabapentin, depicting a cyclohexane ring connected to aminomethyl and carboxymethyl groups.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin at 3600 mg/day. The x-axis shows weeks divided into a 4-week dose titration period and a 4-week fixed dose period. Gabapentin shows a decrease in mean pain score over time, while placebo remains relatively steady.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain score over seven weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks starting at baseline; the y-axis represents mean pain scores. The graph highlights a 3-week dose titration period followed by a 4-week fixed dose period, with Gabapentin doses showing lower mean pain scores than placebo over time.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses across two studies. Study 1 shows 12% response for PBO and 29% for GBP 3600 mg. Study 2 shows 14% response for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing difference percentages across three studies (Study a, Study b, Study c) for various gabapentin daily doses (600 mg, 900 mg, 1200 mg, 1800 mg). The horizontal axis represents daily dose in milligrams, and the vertical axis represents difference percentage, with data points marked for each study at different dose levels.*

FDA Label Image

Label Image (Lbl500904889)

Label for Gabapentin 100 mg capsules from A-S Medication Solutions, Libertyville, IL. The label includes the NDC 50090-4889-0, storage instructions to keep capsules at 68 to 77 degrees Fahrenheit, and indicates a package size of 33 unit dose capsules. A QR code for dosage instructions is present along with a lot number and product number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.